Lento Bio to present LB-01 presbyopia update at Eyecelerator 2026

Lento Bio will present updates on LB-01, its investigational eye drop for presbyopia, at Eyecelerator @ AAO 2026 in New Orleans on Oct. 8. The presentation will outline the company’s effort to restore lens flexibility and position LB-01 as a disease-modifying approach to age-related near-vision loss.

Why it matters: - Presbyopia affects nearly everyone by their 40s and is often the first noticeable aging-related vision problem. - Lento Bio is developing LB-01 as a treatment designed to restore the lens’s natural flexibility instead of only easing symptoms. - If successful, the program could represent a different approach to age-related near-vision loss.

What happened: - Lento Bio announced that it will present its lead program, LB-01, at Eyecelerator @ American Academy of Ophthalmology 2026. - The meeting will be held in New Orleans on Oct. 8, 2026. - Kris Barnes, PhD, chief executive officer of Lento Bio, will present the update.

The details: - The presentation is scheduled for Oct. 8, 2026, at 1:55 p.m. CT. - The session is listed under Anterior Segment. - The presentation will take place in Room 243-245 at the Ernest N. Morial Convention Center in New Orleans. - LB-01 is an investigational therapeutic in development for presbyopia. - The program is designed to soften the aging lens by breaking the crosslinks that make it stiff. - The stated goal is to restore accommodation and near vision. - Barnes said presbyopia is a first symptomatic aging disorder for many people and described LB-01 as a potential disease-modifying therapy rather than a symptomatic one. - Lento Bio develops eye drops intended to reverse molecular hallmarks of lens aging. - More information is available in the company’s announcement. - Lento Bio also shared a social media link on LinkedIn.

Between the lines: - The presentation gives Lento Bio a public forum to frame LB-01 as more than a standard presbyopia treatment. - The company is signaling that its pitch is centered on lens rejuvenation, not temporary vision correction. - The update may help the company build attention with ophthalmology specialists ahead of future development milestones.

What’s next: - Lento Bio will present the program update on Oct. 8 in New Orleans. - The Eyecelerator appearance may be used to share additional results or development progress with the ophthalmology community. - The company’s next visible step appears to be continued advancement of LB-01 as an investigational therapy for presbyopia.